LY3314814: Phase II/III ongoing

AstraZeneca and Eli Lilly said an IDMC recommended continuation of the double-blind, placebo-controlled, international Phase II/III AMARANTH trial evaluating 20 and 50 mg oral AZD3293 once daily for 1...